The University of Arizona

SIROCCO

Summary: 

A multicenter, randomized, double-blind parallel group, placebo-controlled phase 3 efficacy and study of Benralizumab added to high-dose ICS plus LABA in patients with uncontrolled asthma.


Researchers: 

Research Specialties: 
Asthma